CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 21, 2006--Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a biopharmaceutical company focused on the development and commercialization of oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders, announced today that it has signed an agreement with Althea Technologies, Inc. a contract manufacturing organization (CMO), to manufacture ALTU-238 for use in the planned Phase III clinical trials of that product candidate. ALTU-238 is being developed as a subcutaneously administered, once-per-week formulation of human growth hormone that employs Altus’ proprietary protein crystallization and formulation technology.
